<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">JNK (c-Jun N-terminal Kinase) Protein</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MAPK8 (JNK1), MAPK9 (JNK2), MAPK10 (JNK3)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>MAPK8: 10q11.22, MAPK9: 5q35.1, MAPK10: 4q21.3</td>
</tr>
<tr>
<td class="label">UniProt IDs</td>
<td>P45983 (JNK1), P45984 (JNK2), P53779 (JNK3)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~46-48 kDa per isoform</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">SP600125</td>
<td>Broad JNK inhibitor</td>
</tr>
<tr>
<td class="label">JNK-IN-8</td>
<td>Selective JNK inhibitor</td>
</tr>
<tr>
<td class="label">CC-401 (CC-930)</td>
<td>JNK inhibitor</td>
</tr>
<tr>
<td class="label">D-JNKI1</td>
<td>Peptide inhibitor</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">MKK4</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">MKK7</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">c-Jun</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Bim (BCL2L11)</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Bcl-2</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Tau (MAPT)</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">JNK (c-Jun N-terminal Kinase) Protein</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MAPK8 (JNK1), MAPK9 (JNK2), MAPK10 (JNK3)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>MAPK8: 10q11.22, MAPK9: 5q35.1, MAPK10: 4q21.3</td>
</tr>
<tr>
<td class="label">UniProt IDs</td>
<td>P45983 (JNK1), P45984 (JNK2), P53779 (JNK3)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~46-48 kDa per isoform</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">SP600125</td>
<td>Broad JNK inhibitor</td>
</tr>
<tr>
<td class="label">JNK-IN-8</td>
<td>Selective JNK inhibitor</td>
</tr>
<tr>
<td class="label">CC-401 (CC-930)</td>
<td>JNK inhibitor</td>
</tr>
<tr>
<td class="label">D-JNKI1</td>
<td>Peptide inhibitor</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">MKK4</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">MKK7</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">c-Jun</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Bim (BCL2L11)</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Bcl-2</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Tau (MAPT)</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">ATF2</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">p53</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1286 edges</a></td>
</tr>
</table>
JNK (c-Jun N-terminal kinase, also known as MAPK8) is a stress-activated serine/threonine protein kinase belonging to the MAPK family. It is activated by cellular stress, inflammatory cytokines, and excitotoxicity, playing complex and context-dependent roles in neuronal survival and death. JNK is particularly implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and other neurodegenerative disorders. [@bhujbal2025]
JNK exists as three isoforms: JNK1 and JNK2 are ubiquitously expressed, while JNK3 is predominantly neuronal and is the major isoform implicated in neurodegeneration. [@moro2023]
JNK proteins share a central kinase domain flanked by N- and C-terminal regions. The kinase domain adopts a typical bilobal structure characteristic of protein kinases. JNK is activated by dual phosphorylation on a Thr-X-Tyr (TXY) motif within its activation loop, catalyzed by upstream MKK4 and MKK7 kinases. The JNK3 isoform contains a unique 30-amino acid C-terminal extension that may confer neuronal specificity. [@reijnders2020]
JNK is activated through a canonical three-tier kinase cascade:
In the healthy brain, JNK regulates:
JNK is strongly activated in [Alzheimer's disease](/diseases/alzheimers-disease) brains, particularly in regions vulnerable to neurodegeneration such as the hippocampus and prefrontal cortex. [@manoharan2023]
JNK directly phosphorylates [tau](/proteins/tau) at multiple pathological sites. In AD brains, p-JNK colocalizes with neurofibrillary tangles, and JNK activity correlates with Braak staging. JNK also phosphorylates the microtubule-associated protein tau (MAPT) gene promoter, potentially altering tau expression levels. [@yoshikawa2023]
[Aβ](/proteins/amyloid-beta) oligomers activate the JNK pathway through multiple mechanisms:
JNK3 is the predominant isoform in dopaminergic neurons of the substantia nigra pars compacta and is implicated in [Parkinson's disease](/diseases/parkinsons-disease) through multiple mechanisms. [@kumar2021]
JNK inhibitors have been tested in clinical trials for inflammatory diseases (rheumatoid arthritis, COPD) with acceptable safety profiles, establishing a foundation for neurodegenerative applications. However, JNK inhibitors have not yet reached Phase 2/3 trials for AD or PD. [@bhujbal2025]
The following diagram shows the key molecular relationships involving JNK (c-Jun N-terminal Kinase) Protein discovered through SciDEX knowledge graph analysis: